A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

IRB/UVA Tracking #
20452
Contact
Contact Phone
Phase
I
Primary purpose
Treatment
Cancer PI
Robert Dreicer
Status
OPEN TO ACCRUAL
Ages
Adult